References
1.
Morgan CL, Jenkins-Jones S, Currie CJ, Rees DA. Evaluation of adverse
outcome in young women with polycystic ovary syndrome versus matched,
reference controls: a retrospective, observational study. J Clin
Endocrinol Metab 2012;97:3251-3260.
2. González F. Inflammation in Polycystic Ovary Syndrome: underpinning
of insulin resistance and ovarian dysfunction. Steroids 2012;77:300-305
3. Ohsawa I, Inoshita H, Ishii M, Kusaba G, Sato N, Mano S, et al.
Metabolic impact on serum levels of complement component 3 in Japanese
patients. J Clin Lab Anal 2010;24:113-118
4. Engström G, Hedblad B, Eriksson KF, Janzon L, Lindgärde F. Complement
C3 is a risk factor for the development of diabetes: a population-based
cohort study. Diabetes 2005;54:570-575
5. Engström G, Hedblad B, Janzon L, Lindgärde F. Complement C3 and C4 in
plasma and incidence of myocardial infarction and stroke: a
population-based cohort study. Eur J Cardiovasc Prev Rehabil
2007;14:392-397
6. Maslowska M, Sniderman A, Germinario R, Cianflone K. ASP stimulates
glucose transport in cultured human adipocytes. Int J Obes Relat Metab
Disord 1997;21:261-266
7. Cianflone K, Roncari DA, Maslowska M, Baldo A, Forden J, Sniderman
AD. Adipsin/acylation stimulating protein system in human adipocytes:
regulation of triacylglycerol synthesis. Biochemistry 1994;33:9489-9495
8. Faraj M, Sniderman A, Cianflone K. ASP enhances in situ lipoprotein
lipase activity by increasing fatty acid trapping in adipocytes. J Lipid
Res 2004;45:657-666
9. Tao Y, Cianflone K, Sniderman A, Colby-Germinario S, Germinario R.
Acylation-stimulating protein (ASP) regulates glucose transport in the
rat L6 muscle cell line. Biochim Biophys Acta 1997;1344:221-229
10. Maslowska M, Scantlebury T, Germinario R, Cianflone K. Acute in
vitro production of acylation stimulating protein in differentiated
human adipocytes. J Lipid Res 1997;38:1-11
11. Fujita T, Fujioka T, Murakami T, Satomura A, Fuke Y, Matsumoto K.
Chylomicron accelerates C3 tick-over by regulating the role of factor H,
leading to overproduction of acylation stimulating protein. J Clin Lab
Anal 2007;21:14-23
12. Peake PW, Kriketos AD, Campbell LV, Charlesworth JA. Response of the
alternative complement pathway to an oral fat load in first-degree
relatives of subjects with type II diabetes. Int J Obes (Lond)
2005;29:429-435
13. van Oostrom AJ, Alipour A, Plokker TW, Sniderman AD, Cabezas MC. The
metabolic syndrome in relation to complement component 3 and
postprandial lipemia in patients from an outpatient lipid clinic and
healthy volunteers. Atherosclerosis 2007;190:167-173
14. Meijssen S, van Dijk H, Verseyden C, Erkelens DW, Cabezas MC.
Delayed and exaggerated postprandial complement component 3 response in
familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol
2002;22:811-816
15. Halkes CJ, van Dijk H, de Jaegere PP, Plokker HW, van Der Helm Y,
Erkelens DW, et al. Postprandial increase of complement component 3 in
normolipidemic patients with coronary artery disease: effects of
expanded-dose simvastatin. Arterioscler Thromb Vasc Biol
2001;21:1526-1530
16. Gursoy Calan O, Calan M, Yesil Senses P, Unal Kocabas G, Ozden E,
Sari KR, et al. Increased adipsin is associated with carotid intima
media thickness and metabolic disturbances in polycystic ovary syndrome.
Clin Endocrinol 2016;85:910-917.
17. Wu Y, Zhang J, Wen Y, Wang H, Zhang M, Cianflone K. Increased
acylation-stimulating protein, C-reactive protein, and lipid levels in
young women with polycystic ovary syndrome. Fertil Steril
2009;91:213-219
18. Oktenli C, Ozgurtas T, Dede M, Sanisoglu YS, Yenen MC, Yesilova Z,
et al. Metformin decreases circulating acylation-stimulating protein
levels in polycystic ovary syndrome. Gynecol Endocrinol 2007;23:710-5.
19. Yang S, Li Q, Song Y, Tian B, Cheng Q, Qing H, et al. Serum
complement C3 has a stronger association with insulin resistance than
high-sensitivity C-reactive protein in women with polycystic ovary
syndrome. Fertil Steril 2011;95:1749-1753
20. Dehdashtihaghighat S, Mehdizadehkashi A, Arbabi A, Pishgahroudsari
M, Chaichian S. Assessment of C-reactive protein and C3 as inflammatory
markers of insulin resistance in women with polycystic ovary syndrome: a
case-control study. J Reprod Infertil 2013;14:197-201.
21. Snyder ML, Shields KJ, Korytkowski MT, Sutton-Tyrrell K, Talbott EO.
Complement protein C3 and coronary artery calcium in middle-aged women
with polycystic ovary syndrome and controls. Gynecol Endocrinol
2014;30:511-515.
22. Rees E, Coulson R, Dunstan F, Evans WD, Blundell HL, Luzio SD, et
al. Central arterial stiffness and diastolic dysfunction are associated
with insulin resistance and abdominal obesity in young women but
polycystic ovary syndrome does not confer additional risk. Hum Reprod
2014;29:2041-2049
23. Watson S, Blundell HL, Evans WD, Griffiths H, Newcombe RG, Rees DA.
Can abdominal bioelectrical impedance refine the determination of
visceral fat from waist circumference? Physiol Meas 2009;30:N53-58
24. Giles JL, Choy E, van den Berg C, Morgan BP, Harris CL. Functional
analysis of a complement polymorphism (rs17611) associated with
rheumatoid arthritis. J Immunol 2015;194:3029-3034
25. Ingram G, Hakobyan S, Hirst CL, Harris CL, Loveless S, Mitchell JP,
et al. Systemic complement profiling in multiple sclerosis as a
biomarker of disease state. Mult Scler 2012;18:1401-1411
26. Hakobyan S, Harris CL, Tortajada A, Goicochea de Jorge E,
García-Layana A, Fernández-Robredo P, et al. Measurement of factor H
variants in plasma using variant-specific monoclonal antibodies:
application to assessing risk of age-related macular degeneration.
Invest Ophthalmol Vis Sci 2008;49:1983-1990
27. Cianflone K, Xia Z, Chen LY. Critical review of
acylation-stimulating protein physiology in humans and rodents. Biochem
Biophys Acta 2003;1609:127-143.
28. Maslowska M, Vu H, Phelis S, Sniderman AD, Rhode BM, Blank D, et al.
Plasma acylation stimulating protein, adipsin and lipids in non-obese
and obese populations. Eur J Clin Invest 1999;29:679-686.
29. Koistinen HA, Vidal H, Karonen SL, Dusserre E, Vallier P, Koivisto
VA, et al. Plasma acylation stimulating protein concentration and
subcutaneous adipose tissue C3 mRNA expression in nondiabetic and type 2
diabetic men. Arterioscler Thromb Vasc Biol 2001;21:1034-1039.
30. Xin Y, Hertle E, van der Kallen CJH, Schalkwijk CG, Stehouwer CDA,
van Greevenbroek MMJ. Longitudinal associations of the alternative and
terminal pathways of complement activation with adiposity: The CODAM
study. Obes Res Clin Pract 2018;12:286-292.
31. Engstrom G, Hedblad B, Janzon L, Lindgarde F. Weight gain in
relation to plasma levels of complement factor 3: results from a
population-based cohort study. Diabetologia 2005;48:2525-2531.
32. Xin Y, Hertle E, van der Kallen CJH, Schalwijk CG, Stehouwer CDA,
van Greevenbroek MMJ. Complement C3 and C4, but not their regulators or
activated products, are associated with incident metabolic syndrome: the
CODAM study. Endocrine 2018;62:617-627.
33. Daan NM, Koster MP, de Wilde MA, Dalmeijer GW, Evelein AM, Fauser
BC, et al. Biomarker profiles in women with PCOS and PCOS offspring: a
pilot study. PLoS One 2016;11(11):e0165033
34. Sivakumar K, Bari MF, Adaikalakoteswari A, Guller S, Weickert MO,
Randeva HS, et al. Elevated fetal adipsin/acylation-stimulating protein
(ASP) in obese pregnancy: novel placental secretion via hofbauer cells.
J Clin Endocrinol Metab 2013;98:4113-4122.
35. Matsunaga H, Iwashita M, Shinjo T, Yamashita A, Tsuruta M, Nagasaka
S, et al. Adipose tissue complement factor B promotes adipocyte
maturation. Biochem Biophys Res Commun 2018;495:740-748.
36. Moreno-Navarette JM, Martinez-Barricarte R, Catalan V, Sabater M,
Gomez-Ambrosi J, Ortega FJ, et al. Complement factor H is expressed in
adipose tissue in association with insulin resistance. Diabetes
2010;59:200-209.
37. Harboe M, Ulvund G, Vien L, Fung M, Mollnes TE. The quantitative
role of alternative pathway amplification in classical pathway induced
terminal complement activation. Clin Exp Immunol 2004;138:439-446.
38. Harboe M, Garred P, Karlstrøm E, Lindstad JK, Stahl GL, Mollnes TE.
The down-stream effects of mannan-induced lectin complement pathway
activation depend quantitatively on alternative pathway amplification.
Mol Immunol 2009;47:373-380.
39. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting
compared with nonfasting triglycerides and risk of cardiovascular events
in women. J Am Med Assoc 2007;298:309-315.
40. Vaisar T, Pennathur S, Green P, Gharib S, Hoofnagle A, Cheung M, et
al. Shotgun proteomics implicates protease inhibition and complement
activation in the antiinflammatory properties of HDL. J Clin Invest
2007;117:746-756.
41. Haapasalo K, van Kessel K, Nissilä E, Metso J, Johansson T,
Miettinen S, et al. Complement factor H is expressed in adipose tissue
in association with insulin resistance. Diabetes 2010;59:200-209.
42. Martínez A, Pío R, López J, Cuttitta F. Expression of the
adrenomedullin binding protein, complement factor H, in the pancreas and
its physiological impact on insulin secretion. J Endocrinol
2001;170:503-511.
43. Charlesworth JA, Peake PW, Campbell LV, Pussell BA, O’Grady S,
Tzilopoulos T. The influence of oral lipid loads on acylation
stimulating protein in healthy volunteers. Int J Obes Relat Metab Disord
1998;22:1096-1102.
44. Peake PW, Kriketos AD, Campbell LV, Charlesworth JA. Response of the
alternative complement pathway to an oral fat load in first-degree
relatives of subjects with type II diabetes. Int J Obes 2005;29:429-435.
45. Kalant D, Phélis S, Fielding BA, Frayn KN, Cianflone K, Sniderman
AD. Increased postprandial fatty acid trapping in subcutaneous adipose
tissue in obese women. J Lipid Res 2000;41:1963-1968
46. Saleh J, Summers L, Cianflone K, Fielding B, Sniderman A, Frayn K.
Coordinated release of acylation stimulating protein (ASP) and
triacylglycerol clearance by human adipose tissue in vivo in the
postprandial period. J Lipid Res 1998;39:884-891.
47. Gabrielsson B, Johansson J, Lönn M, Jernås M, Olbers T, Peltonen M,
et al. High expression of complement components in omental adipose
tissue in obese men. Obes Res 2003;11:699-708
48. Munkonda MN, Martin J, Poirier P, Carrington A, Biron S, Lebel S, et
al. Acylation stimulating protein reduction precedes insulin
sensitization after BPD-DS bariatric surgery in severely obese women.
Nutr Diabetes 2012; 2:e41. doi: 10.1038/nutd.2012.13.
49. Schrauwen P, Hesselink MK, Jain M, Cianflone K.
Acylation-stimulating protein: effect of acute exercise and endurance
training. Int J Obes 2005;29:632-638.
50. Ricklin D, Lambris JD. Therapeutic control of complement activation
at the level of the central component C3. Immunobiology
2016;221:740-746.